These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32820530)

  • 1. Assessing and mitigating the interference of ALX148, a novel CD47 blocking agent, in pretransfusion compatibility testing.
    Kim TY; Yoon MS; Hustinx H; Sim J; Wan HI; Kim H
    Transfusion; 2020 Oct; 60(10):2399-2407. PubMed ID: 32820530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal anti-CD47 interference in red cell and platelet testing.
    Velliquette RW; Aeschlimann J; Kirkegaard J; Shakarian G; Lomas-Francis C; Westhoff CM
    Transfusion; 2019 Feb; 59(2):730-737. PubMed ID: 30516833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile.
    Kauder SE; Kuo TC; Harrabi O; Chen A; Sangalang E; Doyle L; Rocha SS; Bollini S; Han B; Sim J; Pons J; Wan HI
    PLoS One; 2018; 13(8):e0201832. PubMed ID: 30133535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Novel Monoclonal Antibody Therapeutics on Blood Bank Pretransfusion Testing.
    Mei Z; Wool GD
    Hematol Oncol Clin North Am; 2019 Oct; 33(5):797-811. PubMed ID: 31466605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How do transfusion services manage patients taking therapies such as anti-CD38 and anti-CD47 known to interfere with red blood cell compatibility testing?
    Murphy MF; Rajbhandary S; Carayiannis S; Cohn CS
    Transfusion; 2024 Jul; 64(7):1217-1222. PubMed ID: 38767410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evorpacept-Induced Interference and Application of a Novel Mitigation Agent, Evo-NR, in Pretransfusion Testing.
    Yoon E; Kim TY; Kim H; Cho D
    Transfus Med Hemother; 2024 Jun; 51(3):185-192. PubMed ID: 38867811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia.
    Brierley CK; Staves J; Roberts C; Johnson H; Vyas P; Goodnough LT; Murphy MF
    Transfusion; 2019 Jul; 59(7):2248-2254. PubMed ID: 31183877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-stage papain-indirect antiglobulin test and LISS direct agglutination are not appropriate for pretransfusion screening for unexpected antibodies.
    Pereira A; Mazzara R; Gelabert A; Castillo R
    Haematologica; 1991; 76(6):475-8. PubMed ID: 1820984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of new myeloma agents on the transfusion laboratory.
    Jones AD; Moayeri M; Nambiar A
    Pathology; 2021 Apr; 53(3):427-437. PubMed ID: 33707006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment with Daudi cells eliminates anti-CD47 monoclonal antibody interference in immunohematology testing.
    Wei H; Cui Y; Ren D; Jiang X; Fu W; Mu S; Yang L; Chen J
    Blood Transfus; 2024 Jan; 22(1):20-29. PubMed ID: 37847207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells.
    Piccione EC; Juarez S; Tseng S; Liu J; Stafford M; Narayanan C; Wang L; Weiskopf K; Majeti R
    Clin Cancer Res; 2016 Oct; 22(20):5109-5119. PubMed ID: 27126995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
    Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS
    Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Just eat it: A review of CD47 and SIRP-α antagonism.
    Oronsky B; Carter C; Reid T; Brinkhaus F; Knox SJ
    Semin Oncol; 2020; 47(2-3):117-124. PubMed ID: 32517874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New method for overcoming the interference produced by anti-CD38 monoclonal antibodies in compatibility testing.
    Izaguirre EC; Del Mar Luis-Hidalgo M; González LL; Castaño CA
    Blood Transfus; 2020 Jul; 18(4):290-294. PubMed ID: 32530397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity.
    de Silva S; Fromm G; Shuptrine CW; Johannes K; Patel A; Yoo KJ; Huang K; Schreiber TH
    Cancer Immunol Res; 2020 Feb; 8(2):230-245. PubMed ID: 31852716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfusion management in the era of magrolimab (Hu5F9-G4), an anti-CD47 monoclonal antibody therapy.
    Singh N; Staves J; Storry JR; Dinoso J; Renard C; Doshi P; Johnson LDS; Westhoff CM; Murphy MF
    Transfusion; 2023 Dec; 63(12):2377-2383. PubMed ID: 37970740
    [No Abstract]   [Full Text] [Related]  

  • 17. CD47-SIRPα Interactions Regulate Macrophage Uptake of Plasmodium falciparum-Infected Erythrocytes and Clearance of Malaria In Vivo.
    Ayi K; Lu Z; Serghides L; Ho JM; Finney C; Wang JCY; Liles WC; Kain KC
    Infect Immun; 2016 Jul; 84(7):2002-2011. PubMed ID: 27091932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daratumumab Interference in Pretransfusion Testing Is Overcome by Addition of Daratumumab Fab Fragments to Patients' Plasma.
    Werle E; Ziebart J; Wasmund E; Eske-Pogodda K
    Transfus Med Hemother; 2019 Dec; 46(6):423-430. PubMed ID: 31933572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
    Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
    J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy.
    Oostendorp M; Lammerts van Bueren JJ; Doshi P; Khan I; Ahmadi T; Parren PW; van Solinge WW; De Vooght KM
    Transfusion; 2015 Jun; 55(6 Pt 2):1555-62. PubMed ID: 25988285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.